<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05069272</url>
  </required_header>
  <id_info>
    <org_study_id>SYTPIG1M</org_study_id>
    <nct_id>NCT05069272</nct_id>
  </id_info>
  <brief_title>Double-blinded, Vehicle Controlled Study to Evaluate Efficacy &amp; Tolerance of Bakuchiol and Ethyl Linoleate on Acne</brief_title>
  <official_title>A Randomized, Double-blinded, Vehicle Controlled, Monocentric Study to Evaluate the Efficacy and Tolerance of Synergistic Combination of Bakuchiol and Ethyl Linoleate on Mild to Moderate Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ratan K. Chaudhuri</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sytheon Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will be assigned to a active cream or vehicle to compare the cosmetic effects. This&#xD;
      will take place over a 12 week period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 20, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IGA Score</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>IGA score of zero (clear) or one (almost clear)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Facial lesions</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Percent reductions in facial lesion counts for inflammatory and noninflammatory</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total lesion count</measure>
    <time_frame>From baseline to week 2</time_frame>
    <description>Percent change in Global Face Total Lesion Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total lesion count</measure>
    <time_frame>From baseline to week 4</time_frame>
    <description>Percent change in Global Face Total Lesion Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total lesion count</measure>
    <time_frame>From baseline to week 8</time_frame>
    <description>Percent change in Global Face Total Lesion Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total lesion count</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Percent change in Global Face Total Lesion Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGA score</measure>
    <time_frame>From baseline to week 2, 4, 8, 12</time_frame>
    <description>IGA score of zero (clear) or one (almost clear) as compared to vehicle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGA score</measure>
    <time_frame>From baseline to week 4</time_frame>
    <description>IGA score of zero (clear) or one (almost clear)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGA score</measure>
    <time_frame>From baseline to week 8</time_frame>
    <description>IGA score of zero (clear) or one (almost clear)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGA score</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>IGA score of zero (clear) or one (almost clear)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGA score</measure>
    <time_frame>From baseline to week 2, 4, 8 &amp; 12</time_frame>
    <description>IGA score of zero (clear) or one (almost clear) as compared to vehicle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory and non-inflammatory leisons</measure>
    <time_frame>From baseline to week 2</time_frame>
    <description>Percent reductions in facial lesion counts for inflammatory and noninflammatory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory and non-inflammatory leisons</measure>
    <time_frame>From baseline to week 4</time_frame>
    <description>Percent reductions in facial lesion counts for inflammatory and noninflammatory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory and non-inflammatory leisons</measure>
    <time_frame>From baseline to week 8</time_frame>
    <description>Percent reductions in facial lesion counts for inflammatory and noninflammatory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory and non-inflammatory leisons</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Percent reductions in facial lesion counts for inflammatory and noninflammatory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory and non-inflammatory leisons</measure>
    <time_frame>From baseline to week 2, 4, 8 &amp; 12</time_frame>
    <description>Percent reductions in facial lesion counts for inflammatory and noninflammatory as compared to vehicle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post inflammatory hyperpigmentation</measure>
    <time_frame>From baseline to week 2</time_frame>
    <description>Percent reduction in overall post inflammatory hyperpigmentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post inflammatory hyperpigmentation</measure>
    <time_frame>From baseline to week 4</time_frame>
    <description>Percent reduction in overall post inflammatory hyperpigmentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post inflammatory hyperpigmentation</measure>
    <time_frame>From baseline to week 8</time_frame>
    <description>Percent reduction in overall post inflammatory hyperpigmentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post inflammatory hyperpigmentation</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Percent reduction in overall post inflammatory hyperpigmentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post inflammatory hyperpigmentation</measure>
    <time_frame>From baseline to week 2, 4, 8 &amp; 12</time_frame>
    <description>Percent reduction in overall post inflammatory hyperpigmentation as compared to vehicle</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Synergistic combination of Bakuchiol and Ethyl Linoleate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No active ingredients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bakuchiol and Ethyl Linoleate</intervention_name>
    <description>A synergistic combination of Bakuchiol and Ethyl Linoleate</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>No actives</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy female volunteers, aged 18 years or older;&#xD;
&#xD;
          -  with mild to moderate acne;&#xD;
&#xD;
          -  Subjects must have between 10-100 non-inflammatory lesions and 10-50 inflammatory&#xD;
             lesions but no more than 2 nodular lesions and no cysts on their face.&#xD;
&#xD;
          -  If applicable, users of estrogens/birth control pills must have been on the treatment&#xD;
             regimen for at least 3 months and be willing to continue use for study duration;&#xD;
&#xD;
        Females of child-bearing potential (FCBP): A female is considered not to be of childbearing&#xD;
        potential if she is post-menopausal with at least 12 consecutive months of amenorrhea or&#xD;
        has undergone surgical sterilization. While on the study, FCBP who engage in activity in&#xD;
        which conception is possible must use one of the approved contraceptive options described&#xD;
        below:&#xD;
&#xD;
          -  Option 1: Any one of the following highly effective methods: hormonal contraception&#xD;
             (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device&#xD;
             (IUD); tubal ligation; or partner's vasectomy; OR&#xD;
&#xD;
          -  Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of&#xD;
             natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier&#xD;
             method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c)&#xD;
             contraceptive sponge with spermicide.&#xD;
&#xD;
          -  Willing to follow study instructions and available to attend the study visits;&#xD;
&#xD;
          -  Willing to provide written informed consent and sign photography release&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female subjects: Self-reported pregnant or breast feeding, or planning to become&#xD;
             pregnant during the course of the study;&#xD;
&#xD;
          -  Known allergy or hypersensitivity to acne treatment products;&#xD;
&#xD;
          -  Current skin disease of any type in the test area (e.g. eczema, psoriasis, rosacea,&#xD;
             seborrheic dermatitis, vitiligo, etc.), or under the treatment of a doctor for any&#xD;
             skin condition;&#xD;
&#xD;
          -  Have any cystic acne, acne conglobate, acne fulminans, or secondary acne (chloracne or&#xD;
             drug-induced acne) in the test area;&#xD;
&#xD;
          -  Any conditions on the test site that would interfere with evaluations (i.e. tattoos,&#xD;
             scars, open cuts, sunburn, piercings, excessive hair, etc.);&#xD;
&#xD;
          -  Use of topical treatments such as OTC (over the counter) acne medication topical&#xD;
             anti-inflammatory medications, salicylic acid, corticosteroids, antibiotics,&#xD;
             anti-bacterials, peroxide-containing products, or retinoids within 2 weeks of&#xD;
             baseline;&#xD;
&#xD;
          -  Use of depigmenting medications such as hydroquinone during the 14 days prior to the&#xD;
             study start; Insulin dependent diabetes;&#xD;
&#xD;
          -  Concurrent medication that might affect the response to the test articles including&#xD;
             routine use of anti-inflammatory medications, anti-histamines, and steroids;&#xD;
&#xD;
          -  History of Crohn's disease, or clinically significant enteritis (regional enteritis,&#xD;
             ulcerative colitis, pseudomembranous colitis, antibiotic-associated colitis);&#xD;
&#xD;
          -  Microdermabrasion or laser treatment in the test area within six months of the study;&#xD;
&#xD;
          -  Medical condition which, in the opinion of the Investigator, would compromise the&#xD;
             safety of the subject or confound study results;&#xD;
&#xD;
          -  Use of systemic antibiotics, corticosteroids, antimalarials or oral dapsone within 4&#xD;
             weeks of baseline;&#xD;
&#xD;
          -  Use of other anti-acne medications, including isotretinoin or spironolactone, within 6&#xD;
             months of baseline;&#xD;
&#xD;
          -  Participation on an investigational drug study within 4 months of the baseline visit.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barrie Drewitt</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princeton Consumer Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jack Donnelly</last_name>
    <phone>44(0)1617911797</phone>
    <email>jack@princetonconsumer.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Terrie Bennett</last_name>
    <phone>44(0)1245 934050</phone>
    <email>Terrie@princetonconsumer.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Princeton Consumer Research Corp</name>
      <address>
        <city>Chelmsford</city>
        <state>England</state>
        <zip>CM2 6UA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terrie Bennett Bennett</last_name>
      <phone>44(0)1245 934050</phone>
    </contact>
    <investigator>
      <last_name>Barrie Drewitt Drewitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sytheon Ltd.</investigator_affiliation>
    <investigator_full_name>Ratan K. Chaudhuri</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan on sharing IPD to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

